Literature DB >> 11571362

Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.

P Genton, P Gelisse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11571362     DOI： 10.1212/wnl.57.6.1144-b

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  Improvement of early diagnosed post-anoxic myoclonus with levetiracetam.

Authors:  Marion Venot; Nicolas Weiss; Sophie Espinoza; Audrey Imbert; Jean-Marc Tadie; Jean-Yves Fagon; Emmanuel Guerot; Jean-Luc Diehl
Journal:  Intensive Care Med       Date:  2010-09-25       Impact factor: 17.440

Review 2.  Benefit-risk assessment of levetiracetam in the treatment of partial seizures.

Authors:  Bassel Abou-Khalil
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Levetiracetam in three cases of progressive myoclonus epilepsy.

Authors:  Savvas Papacostas; Elena Kkolou; Eleftherios Papathanasiou
Journal:  Pharm World Sci       Date:  2007-01-23

4.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.